Sanofi Consumer Healthcare India LtdNSE: SANOFICONR
Open the Sanofi Consumer Healthcare India Ltd page
Follow Sanofi Consumer Healthcare India LtdFree account. Get a note when Sanofi Consumer Healthcare India Ltd files.
Q1 FY27 results analysis · July 28, 2026

Sanofi Consumer Healthcare India Ltd (SANOFICONR) Q1 FY27 Results Analysis: EBITDA Margin Expands 611 bps, PAT Grows 23.7%

+13.3%PAT year on year, Rs. 68.80 Cr
Cofacto ResearchPublished July 28, 20262 min readPositive read
Quick summary

Sanofi Consumer Healthcare India Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 235.70 Cr (+6.70% YoY) and PAT growth of +13.30% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateJuly 28, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 235.70 Cr (+6.70% YoY)
PAT (Q1)Rs. 68.80 Cr (+13.30% YoY)
EBITDA margin37.89% (+611 bps YoY)
EPS (Q1)Rs. 29.87 (+13.30% YoY)
Market capRs. 10,858.01 Cr
CMPRs. 4,707.20

Quarter Snapshot

Sanofi Consumer Healthcare India reported Q1 FY27 with EBITDA margin expanding 611 bps YoY to 37.89% and normalized PAT growing 23.7% YoY, driven by raw material tailwinds and operating leverage. Domestic sales grew 12% YoY aided by product relaunches, though overall revenue growth of 6.7% lagged the IPM due to export decline. Strong cash generation and a net cash balance sheet provide financial flexibility.

Key Investment Insights

Key Positives

  • EBITDA margin expanded 611 bps YoY to 37.89%
  • Normalized PAT grew 23.7% YoY
  • Operating cash flow for H1 FY27 improved to Rs.109.6 Cr from Rs.17.9 Cr in H1 FY26
  • Domestic sales grew 12% YoY aided by product relaunch
  • Free cash flow of Rs.108.8 Cr in H1 FY27

Risk Factors

  • Overall revenue growth of 6.7% YoY trailed IPM growth of 12.1%, implying export sales likely declined
  • Trade receivables rose 68% to Rs.49.8 Cr and inventories rose 51.4% to Rs.93.7 Cr, indicating working capital build
  • Sequentially, EBITDA margin contracted 85 bps from Q4FY26's 38.74% to 37.89% as other expenses grew faster than revenue

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.